Jump to main content
Jump to site search

Issue 19, 2018
Previous Article Next Article

Gold nanoparticles and reduced graphene oxide-amplified label-free DNA biosensor for dasatinib detection

Author affiliations

Abstract

Dasatinib or sprycel is an anticancer drug for treatment of chronic myelogenous leukemia, prostate cancer, and some of the other cancers with several adverse effects. In this research, we suggest an amplified biosensor, based on a glassy carbon electrode modified with ds-DNA, for detection of dasatinib in aqueous solutions. The study also recommends reduced graphene oxide (rGO) and gold nanoparticles (Au-NPs) (Au-NPs/rGO/ds-DNA/GC) for the same purpose. The Au-NPs/rGO/GC was/were characterized using Atomic Force Microscopy (AFM) and Electrochemical Impedance Spectroscopy (EIS) methods. The guanine oxidation peak current of ds-DNA was selected as a signal for the analysis of dasatinib in the concentration range of 0.03–5.5 μM. This was carried out with the help of the differential pulse voltammetry method. Moreover, binding energy investigation showed an equilibrium constant (Ka) equal to 2.25 × 105 M−1 between dasatinib and ds-DNA. The Au-NPs/rGO/ds-DNA/GC was used for dasatinib analysis in tablet and urine samples.

Graphical abstract: Gold nanoparticles and reduced graphene oxide-amplified label-free DNA biosensor for dasatinib detection

Back to tab navigation

Supplementary files

Publication details

The article was received on 29 Jul 2018, accepted on 05 Sep 2018 and first published on 06 Sep 2018


Article type: Paper
DOI: 10.1039/C8NJ03783C
Citation: New J. Chem., 2018,42, 16378-16383
  •   Request permissions

    Gold nanoparticles and reduced graphene oxide-amplified label-free DNA biosensor for dasatinib detection

    F. Tahernejad-Javazmi, M. Shabani-Nooshabadi and H. Karimi-Maleh, New J. Chem., 2018, 42, 16378
    DOI: 10.1039/C8NJ03783C

Search articles by author

Spotlight

Advertisements